Featured Posts
National Review
Telehealth Is Less Promising Than It First Seemed
A key issue facing Congress in its postelection, “lame duck” session is whether to extend regulatory flexibilities expiring at year end that make telehealth services more…
City Journal
The FTC Jettisons Economics—and Law
The Federal Trade Commission is stepping up its pursuit of its new favorite bogeyman: Pharmacy Benefit Managers. Two months ago, the FTC issued an …
HeartLand Daily News
FDA Hid COVID Shot Side Effects—Congressional Report
Heartland Daily News cited CEI on COVID public health concerns Joel Zinberg, M.D., senior fellow at the Competitive Enterprise Institute and director of the Public…
Search Posts
Op-Eds
ObamaCare’s Killer Device Tax
Much of the political conversation in Washington these days concerns innovation, job creation and competitiveness. But talk is cheap, and elected officials must enact policies…
Op-Eds
The Off-Label Drug War of Words
If knowledge is power and ignorance is bliss, what is power used to prevent knowledge from eliminating ignorance? I don’t know; ask the FDA (U.S.
Heartlander
Critical Drug Shortages Reaching Crisis
From Ashley Bateman's article on Heartland.org: But according to Greg Conko, a senior fellow at the Competitive Enterprise Institute, more mandates on companies…
Medical Progress Today
Mayo v. Prometheus and Diagnostic Patents: What Does the Supreme Court Decision Really Mean?
I finally had a chance to read the Supreme Court's recent decision in the Mayo v. Prometheus Labs case, which invalided two patents claiming methods…
Medical Progress Today
The Orphan Drug Conundrum
It’s not a crisis. Yet. Bigger health care issues loom. Right now. There are still fortunes to be made. While it lasts. But one could…
Medical Progress Today